Orexin-Driven Wakefulness
Orexin neurons keep the brain awake and alert.
- ~70,000: Orexin neurons (hypothalamus) (small, powerful population)
- OX1 & OX2: Receptor subtypes (Gq-coupled GPCRs)
- 4+: Wake centers targeted (LC, TMN, raphe, BF)
- 100%: Baseline wake signal (normal daytime tone)
Orexin neuron anatomy
Neurons cluster tightly within the lateral hypothalamus.
Receptor distribution
OX1 favors locus coeruleus; OX2 favors TMN, cortex.
Arousal maintenance
Continuous orexin firing sustains stable daytime wakefulness.
Orexin neuron loss causes narcolepsy — the opposite disorder.
Suvorexant & Lemborexant Dosing
A dual orexin receptor antagonist is swallowed before bed.
- ~12 h: Suvorexant half-life (oral tablet)
- ~17–19 h: Lemborexant half-life (oral tablet)
- 1–4 h: Time to peak plasma (Tmax range)
- 10–20 mg: Typical dose (patient-specific)
Absorption
Drug crosses the gut wall into the bloodstream.
Blood-brain barrier crossing
Lipophilic molecule reaches hypothalamic receptors quickly.
Dose-dependent exposure
Higher dose raises peak brain drug concentration.
Both drugs are DORAs — dual orexin receptor antagonists.
Competitive OX1/OX2 Receptor Blockade
Drug molecules outcompete orexin for the same binding pocket.
- Competitive: Binding mode (reversible antagonism)
- High: OX2 affinity (key sleep-relevant target)
- ~65–80%: Occupancy at standard dose (typical clinical range)
- Displaced: Orexin fate (blocked, not destroyed)
Competitive kinetics
Drug and orexin compete for the same receptor pocket.
Occupancy dynamics
Higher plasma levels push occupancy toward saturation.
Reversible mechanism
Blockade fades naturally as the drug clears.
DORAs block signaling without themselves activating the receptor.
Wake-Promoting Circuits Lose Drive
Downstream arousal centers quiet without orexin input.
- Reduced: Locus coeruleus firing (norepinephrine drops)
- Reduced: TMN histamine tone (histaminergic signal fades)
- Declining: Cortical arousal (EEG shifts toward sleep)
- Falling: Wake signal strength (tracks occupancy rise)
Downstream silencing
Norepinephrine and histamine output taper off.
Multi-hub effect
One blockade point dims several arousal hubs.
Gradual transition
Arousal fades smoothly, not abruptly.
This graded quieting differs from benzodiazepine-style global sedation.
Natural Sleep Onset
Lowered arousal signaling finally lets sleep occur.
- ~30–45 min: Median time to sleep onset (dose-dependent)
- None: GABA-A receptor involvement (distinct mechanism)
- Low: Dependence risk vs benzodiazepine (no reinforcing euphoria)
- Preserved: Sleep architecture (normal REM/NREM cycling)
Sleep architecture preserved
REM and NREM stages remain largely normal.
No GABA-A involvement
Mechanism avoids the benzodiazepine receptor pathway entirely.
Dependence profile
Lower abuse liability than classic hypnotics.
Orexin blockade sleep differs fundamentally from GABA-A sedation.